Rodríguez-Otero et al., 2017 - Google Patents
Is immunotherapy here to stay in multiple myeloma?Rodríguez-Otero et al., 2017
View HTML- Document ID
- 11429486334466260948
- Author
- Rodríguez-Otero P
- Paiva B
- Engelhardt M
- Prósper F
- San Miguel J
- Publication year
- Publication venue
- Haematologica
External Links
Snippet
Immune escape and impaired immune surveillance have been identified as emerging hallmarks of cancer. 1 Multiple myeloma represents a genuine example of disrupted immune surveillance characterized by: impaired antibody production, deregulation of the T …
- 206010035226 Plasma cell myeloma 0 title abstract description 115
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodríguez-Otero et al. | Is immunotherapy here to stay in multiple myeloma? | |
| Zhu et al. | Combination strategies to maximize the benefits of cancer immunotherapy | |
| Vago et al. | Immune escape and immunotherapy of acute myeloid leukemia | |
| Hayes | Cellular immunotherapies for cancer | |
| Kabacaoglu et al. | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options | |
| Bagley et al. | CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges | |
| Cohen et al. | How to train your T cells: overcoming immune dysfunction in multiple myeloma | |
| Frankel et al. | The role of tumor microenvironment in cancer immunotherapy | |
| Whiteside et al. | Emerging opportunities and challenges in cancer immunotherapy | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Rossi et al. | Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells | |
| Austin et al. | Harnessing the immune system in acute myeloid leukaemia | |
| Chester et al. | Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy | |
| Lamb et al. | Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future | |
| Beyar-Katz et al. | Novel approaches to acute myeloid leukemia immunotherapy | |
| Pianko et al. | Immune checkpoint blockade for hematologic malignancies: a review | |
| Miller et al. | NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction | |
| Bachireddy et al. | Haematological malignancies: at the forefront of immunotherapeutic innovation | |
| Leblay et al. | Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities | |
| Przespolewski et al. | Advances in immunotherapy for acute myeloid leukemia | |
| Yamamoto et al. | Harnessing the immune system against multiple myeloma: challenges and opportunities | |
| Mucciolo et al. | The dark side of immunotherapy: Pancreatic cancer | |
| Jung et al. | Immunotherapy for the treatment of multiple myeloma | |
| Riether et al. | From" magic bullets" to specific cancer immunotherapy | |
| Clara et al. | Harnessing natural killer cells for the treatment of multiple myeloma |